irinotecan / selectivity Cancer Research Results

CPT-11, irinotecan: Click to Expand ⟱
Features:
Irinotecan is a chemotherapy drug widely used to treat several solid tumors. It is a semisynthetic camptothecin derivative and functions primarily as a topoisomerase I inhibitor.
-Active metabolite: SN-38 (much more potent than irinotecan itself)

Common Regimens
Regimen Components
FOLFIRI Folinic acid + 5-FU + Irinotecan
FOLFIRINOX 5-FU + Leucovorin + Irinotecan + Oxaliplatin
XELIRI / CAPIRI Capecitabine + Irinotecan

Potential strategies to sensitize tumors to irinotecan:
Strategy	       Rationale
GSH depletion	       Reduces detox of SN-38
PRDX/TXNRD stress	Lowers redox buffering
Glycolysis inhibition	Limits repair energy
PEMF / AgNPs	        ↑ ROS, ↑ drug uptake
Timing selenium	        Avoid boosting antioxidant defenses during therapy
Report of combining CPT-11 and SeNPs to increase NRF2 in normal cells(chemoprotective) and decrease NRF2 in cancer cells(chemosentization).
selectivity, selectivity: Click to Expand ⟱
Source:
Type:
The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues.

Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance

Factors that affect selectivity:
1. Ability of Cancer cells to preferentially absorb a product/drug
-EPR-enhanced permeability and retention of cancer cells
-nanoparticle formations/carriers may target cancer cells over normal cells
-Liposomal formations. Also negatively/positively charged affects absorbtion

2. Product/drug effect may be different for normal vs cancer cells
- hypoxia
- transition metal content levels (iron/copper) change probability of fenton reaction.
- pH levels
- antiOxidant levels and defense levels

3. Bio-availability
Scientific Papers found: Click to Expand⟱
4734- SeNPs,  CPT-11,    Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles
- in-vitro, CRC, HCT8 - in-vivo, NA, NA
chemoP↑, ChemoSen↑, P53↑, Apoptosis↑, TumCG↓, Casp↑, Dose↝, NRF2↓, selectivity↑, *NRF2↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

NRF2↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Casp↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose↝, 1,   selectivity↑, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

NRF2↑, 1,  
Total Targets: 1

Scientific Paper Hit Count for: selectivity, selectivity
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:380  Target#:1110  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page